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ABSTRACT
Discoidin Domain Receptor 1 (DDR1) is a collagen receptor tyrosine-kinase that 
contributes to epithelial-to-mesenchymal transition and enhances cancer progression. 
Our previous data indicate that, in breast cancer cells, DDR1 interacts with IGF-1R 
and positively modulates IGF-1R expression and biological responses, suggesting that 
the DDR1-IGF-IR cross-talk may play an important role in cancer.
In this study, we set out to evaluate whether IGF-I stimulation may affect DDR1 
expression. Indeed, in breast cancer cells (MCF-7 and MDA-MB-231) IGF-I induced 
significant increase of DDR1 protein expression, in a time and dose dependent manner. 
However, we did not observe parallel changes in DDR1 mRNA. DDR1 upregulation 
required the activation of the PI3K/AKT pathway while the ERK1/2, the p70/
mTOR and the PKC pathways were not involved. Moreover, we observed that DDR1 
protein upregulation was induced by translational mechanisms involving miR-199a-
5p suppression through PI3K/AKT activation. This effect was confirmed by both 
IGF-II produced by cancer-associated fibroblasts from human breast cancer and by 
stable transfection of breast cancer cells with a human IGF-II expression construct. 
Transfection with a constitutively active form of AKT was sufficient to decrease miR-
199a-5p and upregulate DDR1. Accordingly, IGF-I-induced DDR1 upregulation was 
inhibited by transfection with pre-miR-199a-5p, which also impaired AKT activation 
and cell migration and proliferation in response to IGF-I.
These results demonstrate that, in breast cancer cells, a novel pathway involving 
AKT/miR-199a-5p/DDR1 plays a role in modulating IGFs biological responses. 
Therefore, this signaling pathway may represent an important target for breast 
cancers with over-activation of the IGF-IR axis.
Oncotarget7684www.impactjournals.com/oncotarget
INTRODUCTION
The IGF system has a crucial role in the regulation 
of mammalian development and growth [1, 2, 3]. Notably, 
the two main receptors of the system, the type I IGF-I 
receptor (IGF-IR) and the homolog insulin receptor (IR), 
which occurs in two isoforms (IR-A and IR-B), are often 
overexpresssed in cancer cells and may affect not only the 
early phases of carcinogenesis but also cancer progression 
and cancer resistance to therapies [4–9]. Their cognate 
ligands, IGF-I and IGF-II, are frequently abundant in the 
tumor microenvironment as in fact they can be secreted 
by the tumor stroma and/or by malignant cells [10, 11]. 
While IGF-I binds only to the IGF-IR with high affinity 
and insulin binds only to IR isoforms, IGF-II has high 
affinity for both the IGF-IR and IR-A, which is the IR 
isoform preferentially expressed in cancer cells [12, 13].
In the last decade, the IGF-IR has been considered 
the most appropriate target to hinder IGF system 
deregulation in cancer, as the IGF-IR is mainly involved 
in survival and proliferation control, and, unlike the 
IR, only marginally involved in glucose regulation 
[8]. However, the recent results of phase 2 and phase 
3 trials with IGF-IR blocking agents have been largely 
disappointing [14–16]. 
Recently, we found that discoidin domain receptors 
(DDR1 and DDR2) are candidate molecular partners of 
IR-A [17] and IGF-IR [18]. DDR1 and DDR2 are encoded 
by different genes, and belong to a membrane receptor 
family with tyrosine-kinase activity that bind to and are 
activated by various forms of collagen [19–21]. DDR1 
is widely expressed in normal epithelium, while DDR2 
is expressed in stromal and smooth muscle cells. DDRs 
have 13–15 tyrosine residues in their cytoplasmic domain, 
which serve as binding sites of Src-homology-2 (SH2) 
and phosphotyrosine binding (PTB) domain-containing 
molecules [22]. 
Interestingly, in breast cancer cells and transfected 
fibroblasts, DDR1 appears to be an important regulator 
of IGF-IR expression, trafficking and signaling [18], 
and increases the expression of IGF-IR protein, thus 
potentiating its biological activities. These properties are 
not dependent upon DDR1 action as collagen receptor 
[18]. These data are in agreement with the notion that 
IGF-IR and DDR1 play similar roles not only during 
development but also in cancer [23, 24]. In fact, both IGF-
IR and DDR1 are overexpressed in various malignancies, 
and may sustain epithelial-to-mesenchymal transition, 
invasion, metastases, as well as cancer resistance to 
therapies [4–9, 24, 25]. The observed crosstalk between 
the IGF-IR and DDR1 may have, therefore, important 
implications in development and cancer progression. 
In our present work we asked whether ligand-
stimulated IGF-IR might, in turn, affect DDR1 expression. 
Indeed, in breast cancer cells, exposure to IGFs induced 
upregulation of DDR1 protein through a PI3K/AKT/miR-
199a-5p signaling cascade. Thus, this pathway appears to 
induce a feed-forward mechanism able to sustain IGF-IR-
dependent biological responses.
RESULTS
IGF-I causes DDR1 protein upregulation in 
breast cancer cells
The study was conducted on MCF-7, and MDA-
MB-231 human breast cancer cells. Both these cell lines 
have ductal characteristics and metastatic potential, and 
respond to IGF-I. MCF-7 cells are estrogen receptor 
positive and express high DDR1 and IGF-IR levels [18]. 
In contrast, MDA-MB-231 have characteristics of triple 
negative cells and express lower levels of both DDR1 and 
IGF-IR [18].
Both in MCF-7 and MDA-MB-231 cells, IGF-I 
stimulation significantly upregulated DDR1 protein, in a 
time and dose dependent manner. DDR1 protein increased 
as early as 8 h after incubation with IGF-I and reached 
the maximum of 3–4 folds after 24–72 hours incubation 
(Figure 1A–1B). In contrast, steady-state DDR1 mRNA 
levels showed non-significant changes after IGF-I 
stimulation (Figure 1C–1D), suggesting that translational 
and/or post-translational mechanisms might have a major 
role in DDR1 protein upregulation. 
Dose-response experiments, carried out at 24 h, 
showed that, in both cell lines, 1 nM IGF-I already induces 
noticeable upregulation of DDR1 protein, which reached 
a maximum with 10–50 nM of IGF-I (Figure 1E–1F). In 
contrast, DDR1 mRNA levels showed non-significant 
changes even at higher doses of IGF-I (Figure 1G–1H). 
Treatment of MCF-7 cells with 10 µM cycloheximide, an 
inhibitor of translational elongation, completely blocked 
IGF-I-dependent DDR1 upregulation, suggesting that 
this process is dependent on new protein synthesis and 
confirming that translation mechanisms have a role in 
enhancing DDR1 protein levels (Figure 2). 
We then asked whether DDR1 could be also 
upregulated by other ligands of the IGF system. In 
MCF-7 cells, which are sensitive to insulin stimulation, 
DDR1 was upregulated also by IGF-II and insulin 
(Supplementary Figure 1A), confirming the previously 
observed crosstalk between DDR1 and the insulin receptor 
[17]. In MDA-MB-231 cells, we also observed a DDR1 
response to IGF-II and insulin stimulation (Supplementary 
Figure 1B), although these responses were more transient. 
This is consistent with previous observations that MDA-
MB-231 cells express an inhibitor of the IR tyrosine 
kinase [26, 27], which may regulate the temporal kinetics 
of IR activation. 
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Figure 1: IGF-I induces DDR1 upregulation in breast cancer cells. (A–D) Time course of DDR1 upregulation after IGF-I. 
MCF-7 and MDA-MB-231 cells were starved for 24 h, and then stimulated with IGF-I 50 nM for the indicated time points. For DDR1 
protein expression (A–B) cells were lysed and DDR1 protein expression was measured by western blotting using a polyclonal antibody 
against the C-terminus of DDR1. Immunoblot for α-tubulin was used as control for protein loading. For DDR1 mRNA expression 
(C–D), DDR1 mRNA levels were evaluated by qRT-PCR analysis and values were normalized using S9 as housekeeping control gene. 
(E–H) Dose-response of DDR1 expression after IGF-I. MCF-7 and MDA-MB-231 cells were starved for 24 h, and then stimulated with 
IGF-I at the indicated doses for 24 h. Western blot for DDR1 protein expression and qRT-PCR analysis for DDR1 mRNA expression were 
performed as described in (A–D) and in Methods. Each blot is representative of three independent experiments. Values shown in graphs are 
mean ± SEM of three separate experiments. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
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IGF-I-induced DDR1 upregulation is dependent 
upon the activation of the PI3K/AKT signaling 
cascade but not the ERK1/2, the mTOR or the 
PKC cascades
In MCF-7 cells DDR1 protein upregulation 
induced by IGF-I was completely blocked by the 
phosphatidylinositol-3-kinase (PI3K) inhibitor LY-294002 
(5–10 µM) (Figure 3A), and by the AKT inhibitor AKT 
inhibitor1/2 (10 µM) (Figure 3B), while it was not affected 
by treatment with either the MEK1 inhibitor U0126 (5–
10 µM) (Figure 3C) or the mTOR inhibitor rapamycin 
(5–10 µM) (Figure 3D). Inhibition of the protein Kinase 
C (PKC) with the PKC ζ myristoylated pseudosubstrate 
(P9103-71, 5 µM) or with the broad-range PKC inhibitor 
BIM (1-10 µM) was again ineffective in modulating 
DDR1 levels (data not shown). These data indicate that 
the regulation of DDR1 protein levels by IGF-I requires 
downstream activation of the PI3K/AKT pathway, and that 
the ERK1/2, the mTOR/p70S6K and the PKC cascades do 
not play a role in this process. 
IGF-I induces DDR1 protein upregulation by 
inhibiting miR-199a-5p expression
We then evaluated the hypothesis that a regulatory 
miR could be involved in controlling DDR1 levels. 
Previous work has reported that in leukemia [28] and 
in hepatoma cells [29] decreased miR-199a-5p was 
associated with DDR1 upregulation. We first established 
that transfection of MCF-7 cells with pre-miR-199a-5p 
causes a significant reduction of DDR1 protein (Figure 
4A) and mRNA (Figure 4B). We then evaluated, whether 
IGF-I might affect miR-199a-5p levels in MCF-7 cells. 
Indeed, IGF-I exposure for 24 h caused a significant 
reduction of miR-199a-5p expression levels, as assessed 
by qRT-PCR analysis (Figure 4C).
In order to identify the mechanism by which IGF-I 
regulates miR-199a-5p expression, MCF-7 cells cultured 
in the presence of 50 nM IGF-1 were incubated for 24 
h with various kinase inhibitors, and miR-199a-5p 
expression levels measured. MiR-199a-5p expression was 
increased in the presence of inhibitors of both the PI3K 
Figure 2: Protein synthesis is involved in DDR1 protein upregulation induced by IGF-I. Cycloheximide studies. MCF-7 cells 
were starved for 24 h, pretreated with 10 µg of cycloheximide (CHX) for 1 h and then stimulated with 50 nM of IGF-I for 24 h. Samples 
were analyzed by western blotting for DDR1 expression using a polyclonal antibody against the C-terminus of DDR1. Immunoblot for 
α-tubulin antibody was used as control for protein loading. A representative blot of three independent experiments is shown. *P < 0.05; 
***P < 0.0001.
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Figure 3: IGF-I dependent DDR1 protein upregulation is downstream the PI3K/AKT pathway and does not require 
activation of the ERK1/2 and the mTOR pathways. MCF-7 cells grown with serum stripped 2.5% of FCS for 24 h, were 
pretreated with various kinase inhibitors at the indicated doses for 1 h. Cells were then stimulated with 50 nM IGF-I for 24 h, lysed and 
analyzed by western blotting to evaluate DDR1 protein expression. (A) Cells treated with the PI3K inhibitor LY294002 (LY), and (B) 
the AKT inhibitor1/2 (iAKT). (C) Cells treated with the MEK1 inhibitor U0126, and (D) with the TORC1 inhibitor Rapamycin (Rapa). 
Immunoblot for α-tubulin was used as control for protein loading. Each blot shown is representative of three independent experiments. 
Values are mean ± SEM of three separate experiments. *P < 0.05; ***P < 0.0001; ****P < 0.00001.
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and AKT. In contrast, inhibitors of MEK1 and mTOR 
(TORC1) were ineffective (Figure 4D).
In order to assess whether miR-199a-5p targeted 
DDR1 at its 3′UTR, and whether this action was affected 
by IGF-I, we co-transfected MCF-7 cells with pre-
miR-199a-5p and a wild type DDR1 3′UTR–luciferase 
construct. IGF-I increased the DDR1 3′UTR luciferase 
activity while miR-199a-5p blocked both basal and IGF-I 
stimulated luciferase activity (Figure 4E). Accordingly, 
transfection with pre-miR-199a-5p completely blocked 
IGF-I-induced upregulation of DDR1 protein levels 
(Figure 4F), which were instead increased by transfection 
with anti-miR-199a-5p (Figure 4G). As expected, 
transfection with anti-miR-199a-5p almost completely 
inhibited miR-199a-5p expression (Figure 4F).
IGF-I decreases miR-199a-5p and upregulates 
DDR1 through the PI3K/AKT pathway
To further corroborate these findings indicating 
a crucial role of AKT, we transfected both MCF-7 and 
MDA-MB-231 cells with an active form of AKT (myr-
AKT) or a control empty vector. Cells transfected with 
myr-AKT showed a significant upregulation of DDR1 
protein (Figure 5A–5B) and DDR1 mRNA (Figure 
5C–5D), which were associated with a marked decrease 
in miR-199a-5p expression levels (Figure 5E–5F). 
Collectively, these data confirm that active AKT plays a 
key role in regulating the inhibition of miR-199a-5p and 
consequent DDR1 upregulation. 
Autocrine and paracrine IGFs are able to 
upregulate DDR1 protein in breast cancer cells
Both IGF-I and IGF-II are often produced 
in an autocrine/paracrine manner in the tumor 
microenvironment. In particular, breast cancer cells 
produce autocrine IGF-II, while cancer-associated 
fibroblasts (CAFs) may produce IGF-I and/or IGF-II [30]. 
In order to mimic these in vivo conditions, we incubated 
MCF-7 and MDA-MB-231 cells with conditioned medium 
obtained from CAFs derived from human breast cancers 
(CAFs-CM). CAFs expression of IGF-I and IGF-II was 
documented by qRT-PCR (Supplementary Figure 2). 
Moreover, the concentration of IGF-II protein in CAFs-
CM resulted 1.9 ± 0.02 ng/ml, as measured by a specific 
ELISA. In both cell lines incubation with CAFs-CM for 
24 h induced a significant DDR1 upregulation, which was 
associated with the activation of IGF-IR and AKT (Figure 
6A–6B). 
Moreover, we stably transfected MCF-7 and MDA-
MB-231 cells with an IGF-II expression construct in order 
to induce elevated levels of autocrine IGF-II production. 
Transfected cells showed high production of IGF-II, as 
assessed by qRT-PCR (not shown), constitutive IGF-
IR autophosphorylation and a high degree of AKT and 
ERK1/2 activation (Figure 7A–7B). Importantly, both 
in MCF-7 and MDA-MB-231 cells autocrine IGF-II 
production determined a significant increase in DDR1 
protein (Figure 7A–7B) and mRNA levels (Figure 
7C–7D), which were associated with decreased miR-199a-
5p expression levels (Figure 7E–7F). 
Taken together, these data strongly suggest that 
paracrine/autocrine IGFs production in cancer may result 
in increased DDR1 expression through the activation of a 
PI3K/AKT/miR-199a-5p pathway.
In order to demonstrate that DDR1 downregulation 
by miR-199a-5p is relevant also in cells expressing myr-
AKT or autocrine IGF-II, MCF-7 and MDA-MB-231 
cells stably expressing either myr-AKT or autocrine 
IGF-II were transfected with miR-199a-5p. As shown in 
Figure 8, transfection with miR-199a-5p determined a 
strong inhibition of DDR1 expression levels in those cells.
MiR-199a-5p inhibits proliferation and 
migration of breast cancer cells 
We previously showed that, in breast cancer cells, 
DDR1 silencing by small RNA interference impairs IGF-I 
induced downstream signaling and biologic responses 
[18]. We now evaluated whether DDR1 dowregulation 
induced by miR-199a-5p was also able to affect IGF-I 
signaling and biological effects. Indeed, transfection of 
MCF-7 and MDA-MB-231 cells with pre-miR-199a-
5p significantly downregulated DDR1, and reduced the 
activation of both the AKT and ERK1/2 cascades in 
response to IGF-I (Figure 9A, 9B). Both in MCF-7 (Figure 
9C, 9E) and in MDA-MB-231 cells (Figure 9D, 9F) pre-
miR-199a-5p also significantly inhibited proliferation 
and cell migration through fibronectin-coated filters in 
response to IGF-I. 
Taken together, these data indicate that miR-
199a-5p suppression via autocrine/paracrine IGFs and 
AKT activation causes upregulation of DDR1, which 
enhances IGFs signaling and biological responses, thereby 
delineating a new mechanism by which IGFs enhance 
their own biological responses (Figure 10). 
Computational analysis of microarray gene 
expression in human cells and tissues
We then asked whether DDR1 expression was 
positively correlated with the IGF-IR and/or with the 
homologous receptors insulin receptor (INSR or IR), and/
or with IGF-IR ligands in vivo. To this end, as illustrated in 
Methods, we sought for these correlations across several 
conditions and numerous cell and tissues types using the 
Affymetrix GeneChip Human Genome U133 plus 2.0 
arrays (consisting of 1794 datasets) and the betaMEM 
method. We validated the most statistically relevant MEM 
results in The Cancer Genome Atlas (TCGA) breast 
cancer dataset. By MEM expression analysis, we found 
DDR1 to be strongly and positively correlated with IGF-
IR, IGFBP2, IGFBP5 and AKT expression. A moderate 
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Figure 4: IGF-I induces DDR1 upregulation and increases DDR1 3′UTR activity by inhibiting miR-199a-5p expression. 
(A–B) MiR-199a-5p downregulates DDR1. MCF7 cells cultured in complete medium were transfected with 100 nM of pre-miR-199a-5p or 
scrambled oligonucleotides, as negative control, for 48 h. (A) DDR1 protein expression was determined by western immunoblotting using 
a polyclonal antibody against the C-terminus of DDR1. Immunoblot for α-tubulin was used as control for protein loading. A representative 
blot of three independent experiments is shown. Graph represents densitometric values (mean ± SEM) of three separate experiments. 
**P < 0.005. (B) DDR1 mRNA expression was measured by qRT-PCR analysis and values were normalized using RNU6B as housekeeping 
control gene. Values are mean ± SEM of three separate experiments. *P < 0.05; **P < 0.005. (C) MiR-199a-5p levels are decreased by 
IGF-I. MCF-7 cells were starved for 24 h and then stimulated for further 24 h with IGF-I (50 nM). MiR-199a-5p levels were measured by 
qRT-PCR analysis and normalized against RNU6B as housekeeping control gene. Values are mean ± SEM of three separate experiments. 
**P < 0.005. (D) Inhibition of the PI3K/AKT pathway upregulates miR-199a-5p. MCF-7 cells cultured in medium supplemented with 50 
nM IGF-I were incubated for 24 h with LY294002, AKT inhibitor1/2 (iAKT), U0126, Rapamycin (Rapa) at a dose of 10 μM. MiR-199a-5p 
levels were measured by qRT-PCR analysis and normalized using RNU6B as housekeeping control gene. Values are mean ± SEM of three 
separate experiments. *P < 0.05; **P < 0.001. (E) MiR-199a-5p interacts with the 3′UTR of DDR1. MCF-7 cells were co-transfected with a 
firefly luciferase construct containing the 3′UTR of DDR1 and with pre-miR-199a-5p or control scrambled oligonucleotides (scr). Twenty-
four hours after transfection, cells were stimulated with IGF-I (50 nM) for 24 h. The firefly luciferase activity was normalized to protein 
absorbance. The data are shown as relative luciferase activity of miR-199a-5p-transfected cells as compared to the control (scramble). 
Values are mean ± SEM of three separate experiments performed in triplicate. *P < 0.05; **P < 0.001. (F–G) Effects of pre-miR-199a-5p 
and anti-miR-199a-5p on DDR1 upregulation by IGF-I. MCF-7 cells were transfected with 100 nM of pre-miR-199a-5p, anti-miR-199a-5p 
(anti-miR), or scrambled oligonucleotides as negative control for 24 h, starved for 24 h, and then stimulated with 50 nM of IGF-I for further 
24 h. Samples were analyzed by western blotting using a polyclonal antibody against the C-terminus of DDR1. Immunoblot for α-tubulin 
was used as control for protein loading. A representative blot of three independent experiments is shown. Graph represents mean ± SEM 
of densitometric values of three separate experiments. *P < 0.05; **P < 0.001; ****P < 0.00001. (H) Effect of transfection with a specific 
anti-miR on miR199a5p expression. MCF-7 cells were transfected with 100nM of anti-miR or negative control (scramble) for 48 h. qRT-
PCR analysis showed strong inhibition of miR-199a-5p expression. Normalization was done using RNU6B as housekeeping control gene. 
Values are mean ± SEM of three separate experiments. ****P < 0.00001.
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positive correlation was also found between DDR1 and 
INSR (Table 1). The positive correlation of DDR1 with 
IGF-IR and IGFBP2, but not with AKT, INSR or IGFBP5, 
was further confirmed in the TCGA breast cancer dataset 
(Table 1). Moreover, DDR1 expression negatively 
correlated with DDR2, and weakly correlated with PTEN 
(Table 1). No significant correlation was found between 
DDR1 and IGF-I or IGF-II expression (not shown). 
Conflicting data (or below our stringent p value’s cutoff) 
were found instead when we correlated DDR1 expression 
levels with IGFBP1, IGFBP2 (not shown). 
Next, we evaluated whether miR-199a-5p was 
negatively correlated with DDR1 or with IGF-IR in a 
panel of human cancer histotypes. Indeed, StarBase Pan-
Figure 5: AKT activity is directly involved in DDR1 upregulation and inhibition of miR-199a-5p. (A–D) Transfection with 
myr-AKT upregulates DDR1. MCF-7 and MDA-MB-231 cells were transfected with 4.0 µg of pcDNA.3.1-HA-myr-AKT dominant active 
construct (myr-AKT) or the empty vector pcDNA3.1 (EV) for 48 h and then analyzed by immunoblot using a polyclonal antibody against 
the C-terminus of DDR1. The filters were blotted for total AKT protein to evaluate transfection efficiency. Immunoblot for α-tubulin was 
used as control for protein loading. DDR1 mRNA levels (C–D) were evaluated by qRT-PCR analysis and values were normalized using 
S9 as housekeeping control gene. The experiment shown is representative of three independent experiments. Values are mean ± SEM of 
three separate experiments. *P < 0.05; **P < 0.001; ***P < 0.0001. (E–F) Transfection with myr-AKT downregulates miR-199a-5p. In 
cells transfected as above, miR-199a-5p expression levels were also measured by qRT-PCR analysis and normalized against RNU6B as 
housekeeping control gene. MiR-199a-5p was significantly decreased in myr-AKT transfected cells. Values are mean ± SEM of three 
separate experiments. *P < 0.05; **P < 0.001.
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Cancer analysis showed a significant inverse correlation 
between miR-199a-5p and DDR1 expression in 8/14 
cancer histotypes. In addition, miR-199a-5p also inversely 
correlated with IGF-IR in 2/14 cancer types (Table 2).
Collectively, these data strongly support our in vitro 
data and provide strong evidence that IGF-IR activity may 
induce DDR1 upregulation through decrease of miR-199a-
5p in vivo human breast cancer.
DISCUSSION
We have previously reported that, in breast cancer 
cells and in transfected fibroblasts, the collagen receptor 
DDR1 associates with the IGF-IR in an IGF-I dependent 
manner [18]. This DDR1–IGF-IR interaction leads to 
increased IGF-IR expression, signaling, and enhanced 
mitogenic and migratory response to IGF-I stimulation. In 
murine fibroblasts transfected with the human IGF-IR, the 
concomitant overexpression of DDR1 markedly enhanced 
IGF-IR protein expression and IGF-I-dependent colony 
formation. Both in breast cancer cells and transfected 
fibroblasts, IGF-I stimulation induced rapid tyrosine-
phosphorylation of DDR1, which was accompanied by 
increased association of the DDR1 – IGF-IR complex, 
rapid internalization and sorting to early endosomes [18]. 
Herein we found that, in breast cancer cells, 
exposure to IGF-I induced significant upregulation 
of DDR1 protein, which was not accompanied by 
concomitant similar changes in DDR1 mRNA expression. 
DDR1 protein upregulation was time- and dose-dependent 
following IGF-I exposure, and required IGF-IR tyrosine 
kinase activity, as it was abolished by incubation with the 
specific IGF-IR tyrosine kinase inhibitor NVP-AWE-541 
(not shown). DDR1 upregulation was dependent upon 
the activation of the PI3K/AKT pathway, while the 
ERK1/2 and the mTOR/p70S6K or the PKC pathways 
were not implicated. Accordingly, DDR1 upregulation 
was abolished by inhibitors of PI3K and AKT, and was 
reproduced by transfection with myr-AKT, a constitutively 
activated form of AKT. In order to further dissect the 
mechanisms underlying DDR1 upregulation, we found 
that IGF-I, via activation of the PI3K/AKT pathway, 
induced miR-199a-5p downregulation, which, in turn, 
increased DDR1 protein expression. 
Indeed, transfection of breast cancer cells with 
miR-199a-5p markedly downregulated DDR1 protein 
while miR-199a-5p antagomir upregulated it. DDR1 
mRNA showed less marked changes than DDR1 protein. 
Accordingly, treatment of breast cancer cells with miR-
199a-5p blunted IGF-I signaling and inhibited breast 
cancer cell proliferation and migration in response to 
IGF-I.
MiRNAs are endogenous 18–24 nucleotide single-
stranded RNA molecules that regulate posttranscriptional 
Figure 6: IGF-II from human CAFs-CM is able to upregulate DDR1 protein in breast cancer cells. (A–B) CAFs-CM 
upregulates DDR1. MCF-7 and MDA-MB-231 cells were incubated with conditioned medium (1:3, v/v) from human breast cancer CAFs 
(CAFs-CM). Both in MCF-7 and MDA-MB-231 cells incubation with CAFs-CM for 24 h induced activation of IGF-IR and AKT and a 
significant upregulation of DDR1. Each blot is representative of three independent experiments. Values shown in graphs are mean ± SEM 
of three independent experiments. *P < 0.05; **P < 0.001.
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Figure 7: Autocrine IGF-II markedly upregulates DDR1 in breast cancer cells. (A–B) Constitutively active AKT and ERK1/2 
and DDR1 upregulation in IGF-II transfected cells. (A) MCF-7 and (B) MDA-MB-231 cells were transfected with a c-Myc tagged IGF-II 
expression construct (IGF-II) or a control empty vector (EV). Cells were solubilized and samples analyzed by western blotting with anti-
DDR1, phospho-IGF-IR, phospho-S473-AKT and phospho-ERK1/2 antibodies. The same blots were probed with anti-AKT, anti-ERK1/2, 
anti-β-actin, and anti-c-Myc antibodies to check for protein loading and cell transfection efficiency. Both cell lines showed constitutively 
active IGF-IR, AKT and ERK1/2 and significant increase in DDR1 protein and DDR1 mRNA (C–D) in IGF-II transfected cells. Each blot 
is representative of three independent experiments. Values shown in graphs are mean ± SEM of three independent experiments. *P < 0.05. 
(E–F) Inhibition of miR-199a-5p in IGF-II transfected cells. In cell transfected as above, miR-199a-5p expression levels significantly 
decreased. Values shown in graphs are mean ± SEM of three independent experiments. *P < 0.05; ***P < 0.0001.
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Figure 8: miR199a-5p inhibits DDR1 up-regulation induced by myr-AKT or autocrine IGF-II. MCF-7 and MDA-MB-231 
cells, stably transfected with either pcDNA3.1HA-myr-AKT, control pcDNA3.1HA (A–B), or with c-Myc tagged IGF-II expression construct 
or the relative empty vector (C–D), were starved for 24 h and then transfected with 100 nM miR199a-5p or scramble oligonucleotides for 
48 h. Cells were then evaluated by western blotting for DDR1 expression with a polyclonal antibody against the C-terminus of DDR1. In 
myr-AKT transfected cells AKT expression was also evaluated. β-actin was used as control for protein loading.
Figure 9: In breast cancer cells miR-199a-5p inhibits IGF-I signaling, and cell proliferation and migration. (A–B) IGF-I 
signaling in cells transfected with pre-miR199a-5p. MCF-7 and MDA-MB-231 cells were transfected with 100 nM of pre-miR-199a-5p, or 
negative control for 24 h, starved for 24 h and then stimulated with 50 nM of IGF-I for 5 min. Cells were solubilized and samples analyzed 
by western blotting with phospho-S473-AKT and phospho-ERK1/2 antibodies. The same blots were probed with anti-AKT, anti-ERK1/2 
and anti-β-actin antibodies to check for protein loading. (C–F) Biological responses to IGF-I in cells transfected with pre-miR199a-5p. (C, 
E) MCF-7 and (D, F) MDA-MB-231 cells transfected and cultured as above were stimulated with 50 nM of IGF-I for further 24 h. Cell 
viability was measured by the methyl thiazolyl tetrazolium (MTT) assay, and cell migration through fibronectin-coated filters was evaluated 
in Boyden chambers. Values are mean ± SEM of three separate experiments. *P <0.05; **P < 0.001; ***P < 0.0001;****P < 0.00001.
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gene expression by inhibiting protein translation or 
inducing mRNA degradation [31]. miRNAs interact with 
the 3′-untranslated region (3′-UTR) of target mRNAs, 
and the resulting effects depends on the degree of 
complementarity of each miRNA to the target mRNA. 
Perfect complementarity results in mRNA degradation 
and gene silencing, while partial complementarity results 
in modest targeted mRNA degradation. The final effect 
may also depend on the set of proteins bound to the 3′-
UTR of the target mRNA [31]. Previously, DDR1 has been 
reported to be a target gene of miR-199a-5p, which shows 
only partial complementarity to the 3′UTR of DDR1 
mRNA [29]. Here we confirm that, in breast cancer cells, 
miR-199a-5p reduces the activity of a luciferase construct 
containing the 3′-UTR of the DDR1 mRNA. However, this 
effect of miR-199a-5p is significantly reduced by IGF-I 
stimulation
Interestingly, miR-199a-5p downregulation caused 
by cell exposure to IGF-I was associated with significant 
changes of DDR1 protein but limited changes of DDR1 
mRNA. In contrast, cells transfection with myr-AKT 
or IGF-II expression constructs, caused more marked 
upregulation of DDR1 mRNA. Our present results are in 
agreement with previous work demonstrating an inverse 
relationship between DDR1 and miR-199a-5p. For 
instance, transfection of miR-199a-5p in hepatoma cells 
significantly down-regulated DDR1 protein but did not 
induce changes in DDR1 mRNA expression [29]. However, 
our observation that IGF-I upregulates DDR1 through 
miR-199a-5p downregulation via the PI3K/AKT pathway 
is novel and not previously reported. Nevertheless, our 
data are in accordance with the results of Rane et al. 
indicating that activated AKT is sufficient to downregulate 
miR-199a-5p in cardiac myocytes [32]. Hypoxia 
has been also been reported to reduce miR-199a-5p, 
possibly by inducing AKT activation through the integrin-
linked kinase, ILK [33, 34]. Thus, AKT activation seems 
a nodal upstream regulator of the miR-199a-5p - DDR1 
pathway common to both IGF-I and hypoxia. Data 
obtained in cardiac myocytes suggest that hypoxia-
depend miR-199a-5p downregulation does not require 
transcriptional activity [35]. Therefore, it is likely that 
miR-199a-5p regulation by the IGF-IR/AKT pathway is 
also posttranscriptional and involves miRNAs’ processing 
and/or stability. 
Common events of IGF system dysregulation 
in cancer involve receptor overexpression as well as 
autocrine/paracrine expression of IGF-I and IGF-II [30, 36]. 
We showed that incubation with the conditioned medium 
from CAFs from human breast cancer was able to activate 
IGF-IR, AKT, and upregulate DDR1 in breast cancer cells. 
Moreover, stable transfection of breast cancer cells with 
the IGF-II gene resulted in constitutively activated AKT, 
reduced miR-199a-5p levels, and markedly upregulated 
DDR1 expression. Notably, these cells, which had very 
high AKT activity showed significant upregulation of both 
DDR1 protein and mRNA. 
Taken together, these results indicate that, in breast 
cancer, paracrine/autocrine IGFs are positive modulators 
of DDR1 expression, and help explaining the frequent 
DDR1 overexpression in a variety of malignancies with 
dysregulated IGF axis. 
In view of our previous results indicating that 
DDR1 and IGF-IR form a complex that enhances IGF-I 
effects in cancer cells [18], our present findings suggest 
that the IGF-IR/AKT/miR-199a-5p/DDR1 pathway is an 
important feed-forward mechanism for enhancing IGF-
IR effects (Figure 10). We can therefore hypothesize 
that DDR1 upregulation, by enhancing IGF-IR stability, 
may counteract IGF-IR downregulation by autocrine 
Figure 10: Schematic representation of the positive feedback involving IGF-IR expression and function through the 
AKT/miR-199a-5p/DDR1 pathway. AKT activation through paracrine/autocrine IGFs induces miR-199a-5p inhibition, which in 
turn causes DDR1 upregulation. As previously reported [18], the crosstalk with DDR1 regulates IGF-IR trafficking and expression, and 
enhances IGFs downstream signaling and biological responses.
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expression of IGFs. Indeed, the marked overexpression 
of functional receptors for insulin and IGF-I in most 
malignant cells with concomitant autocrine IGFs secretion 
suggest that ligand-dependent receptor down-regulation 
and degradation may be impaired.
Importantly, by bioinformatics approach, we were 
able to highlight a positive correlation between IGF-IR and 
DDR1 in expression data from several databases including 
the TCGA (The Cancer Genome Atlas) that comprises 
522 primary tumors, 3 metastatic tumors, and 22 tumor-
adjacent normal samples. We found a positive correlation 
between DDR1 and other components of the IGF system, 
such as AKT, IGF-BP2, IGF-BP5 and IR. Moreover, miR-
199a-5p inversely correlated with DDR1 expression in 
several tumors including cancers from breast, lung, ovary, 
thyroid, endometrium and acute myeloid leukemia. These 
data confirm the biological relevance of this IGF-IR/AKT/
miR-199a-5p/DDR1 axis.
The correlation between DDR1 and IR and the 
finding that insulin may also upregulate DDR1, raise 
the possibility that insulin resistance and compensatory 
hyperinsulinemia may enhance DDR1 in neoplastic 
tissues. Further studies are needed to confirm this 
possibility and to fully understand the clinical relevance 
of this effect. 
Notably, IGF-I and IGF-II were also able to 
upregulate DDR1 in triple negative-like MDA-MB-231 
cells, which are known to be responsive to IGF-I [18, 37]. 
However, MDA-MB-231 were less responsive to insulin, 
in agreement to the fact that they overexpress PC1/ENPP1, 
an inhibitor of the IR tyrosine kinase [26, 27], which may 
reduced the intensity of IR activation.
Overactivation of the IGF pathways appears to 
play a fundamental role in cell stemness both in normal 
and cancer tissues through multiple mechanisms [38]. 
Notably, both IGF-IR and DDR1 have been implicated in 
Table 1: Correlations between three different probes for DDR1 and components of the IGF system
betaMEM scores TCGA breast 
Gene Probes + DDR1_208779_X_AT
DDR1_207169_X_
AT DDR1_210749_X_AT
Pearson 
coefficient
(P-value)
IGF1R_225330_at 1.37E-19 3.83E-20 1.12E-20
0.29 
(< 0.00001)
IGF1R_203628_at 6.66E-13 7.03E-13 2.24E-13
IGF1R_203627_at 7.04E-10 4.36E-09 5.52E-10
IGF1R_243358_at 2.28E-07 2.48E-06 2.60E-06
INSR_226450_at 5.79E-08 1.62E-08 2.68E-08 0.09 
(0.035)INSR_213792_s_at 9.07E-07 2.50E-08 4.42E-07
AKT1_207163_s_at 4.52E-10 1.71E-10 9.42E-11 0.069 (0.15)
IGFBP2_202718_at 5.6E-20 1.03E-19 2.44E-20 0.18 (< 0.00001)
IGFBP5_211959_at 5.60E-20 6.79E-14 1.69E-16
0.025 
(0.47)
IGFBP5_211958_at 3.23E-15 6.76E-10 5.97E-10
IGFBP5_203425_s_at 3.64E-10 1.48E-06 6.37E-06
IGFBP5_203424_s_at 9.67E-07 2.17E-06 9.54E-07
IGFBP5_1555997_s_at 1.28E-06 1.29E-05 2.56E-05
Gene Probes −
DDR2_227561_at 4.86E-15 9.14E-13 4.37E-17
−0.26 
(< 0.00001)
DDR2_205168_at 8.17E-14 7.87E-14 1.17E-17
DDR2_225442_at 3.65E-13 1.21E-10 4.37E-15
DDR2_235631_at 6.13E-11 6.18E-08 2.34E-11
PTEN_228006_at 1.25E-07 5.74E-06 8.46E-07 −0.03 (0.48)
Statistically significant correlations between three different probes for DDR1 (i.e., 208779_X_AT, 207169_X_AT, 210749_X_AT) 
and probes for components of the IGF system, according to betaMEM scores ≤ 1 × 10−5. Pearson coefficients and P-values of equiva-
lent genes from TCGA breast analysis are reported in the last column. Gene probes (+), probes positively correlated; Gene probes (−), 
probes negatively correlated. 
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the induction and maintenance of epithelial-mesenchymal 
transition (EMT), one hallmark of stem cells and a critical 
process allowing tissue remodeling during embryogenic 
and tumor invasion and metastasis [39]. MiR-199a-
5p downregulation itself may also play a role in EMT 
by causing E-cadherin loss [40]. Therefore, our present 
data may suggest that the activation of the IGF-IR/AKT/
miR-199a-5p/DDR1 pathway may play a relevant role 
in cancer EMT, cell stemness, invasion and metastasis. 
Moreover, overactivation of IGF system in cancer is 
also increasingly recognized as associated to resistance 
to various anticancer therapies [16, 41−43]. For these 
reasons, in the last decade, much effort has been devoted 
to target the IGF-IR in cancer either with blocking 
antibodies or with small molecules with tyrosine kinase 
inhibiting activity [14]. However, results have been largely 
disappointing, because of the emergence of various and 
not well-characterized mechanisms of resistance [41, 16, 
44, 15, 45]. We hypothesize that the activation of the AKT/
miR-199a-5p/DDR1 pathway may represent one of these 
mechanisms of resistance and that it could be a suitable 
target in malignancies associated with dysregulated IGF 
system. Importantly, our studies raise the possibility that 
DDR1 inhibitors [46, 47] may synergize with IGF-IR 
blocking strategies. Further studies are needed therefore 
to confirm these hypotheses. 
MATERIALS AND METHODS
Materials
IGF-I and IGF-II were from Preprotech (Rocky Hill, 
NJ), lipofectamine 2000 and lipofectamine RNAiMax 
from Life Technologies Inc. Laboratories (Paisley, UK), 
scramble (miR-NC), synthetic pre-miR-199a-5p (miR-
199a-5p), and mirVana miR-199a-5p inhibitor were 
purchased from Ambion (Applied Biosystems, CA, USA), 
fibronectin from Sigma-Aldrich (Saint Louis Missouri, 
USA).
Constructs encoding either pcDNA.3.1-HA-myr-
AKT dominant active construct (AKT) or the empty 
vector pcDNA3.1 (vector) were kindly provided by prof. 
P. Tassone (University “Magna Graecia” of Catanzaro).
Construct encoding 3′UTR clone of DDR1 in 
pMirTarget Vector, the related empty vector (pCMV6) 
and the human IGF-II cDNAs were from OriGene 
Technologies (Rockville, USA). The following kinase 
inhibitors were used: the IGF-IR inhibitor NVP-AEW541 
(Cayman Chemical, Ann Arbor, USA); the PI3 kinase 
inhibitor LY 294002 (Calbiochem, Merck Millipore, 
Nottingham, UK); the MEK1 inhibitor U0126 (Sigma-
Aldrich, Saint Louis Missouri, USA); the TORC1 
inhibitor rapamycin (Sigma-Aldrich); the AKT 1,2 
Table 2: Anticorrelations of expression between miR-199a-5p and DDR1 and IGF-IR across 14 
cancer types from TCGA
DDR1 IGF-IR
Cancer Type Pearson 
coefficient 
P-value Pearson 
coefficient
P-value
Urothelial bladder cancer −0.03 0.64 0.06 0.3
Breast cancer −0.17 0.000001 0.11 0.002
Colon and Rectal adenocarcinoma −0.05 0.3 0.17 0.002
Glioblastoma multiforme −0.37 0.000001 0.07 0.33
Head and neck squamous cell carcinoma −0.11 0.01 0.009 0.84
Chromophobe renal cell carcinoma −0.66 0.000000000001 −0.43 0.00001
Clear cell kidney carcinoma −0.05 0.36 0.07 0.21
Acute Myeloid Leukemia 0.13 0.08 0.05 0.5
Lung adenocarcinoma 0.12 0.01 0.03 0.46
Lung squamous cell carcinoma 0.04 0.42 0.06 0.21
Ovarian serous cystadenocarcinoma −0.19 0.001 0.007 0.89
Cutaneous melanoma −0.22 0.00003 −0.18 0.0004
Papillary thyroid carcinoma −0.11 0.008 0.05 0.16
Uterine corpus endometrial carcinoma −0.3 0.0001 0.17 0.02
Analysis was performed according to starBase Pan-Cancer Platform. Bold typed data are statistically significant.
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inhibitor (Sigma-Aldrich, Saint Louis Missouri, USA). 
Actinomycin D and cycloheximide were purchased from 
Sigma-Aldrich, MTT from Amersham Bioscences.
Cell cultures and conditioned medium analysis
The human cancer cell lines MCF-7, MDA-MB-231 
were purchased from the American Cell Type Culture 
Collection, and cultured according to the manufacturer’s 
instructions. Cells were grown in MEM (Sigma-Aldrich) 
supplemented with 10% fetal bovine serum (Gibco, Life 
Technologies, Carlsbad, CA, USA). Cancer-associated 
fibroblasts (CAFs) from human breast cancer were 
established as previously described [48] and grown in 
Medium-199 (Life Technologies) supplemented with 
10% fetal bovine serum. Conditioned medium from CAFs 
(CAFs-CM) was prepared by incubating CAFs in serum-
free medium for 48 h. IGF-II concentration in CAFs-
CM was measured by a commercially available ELISA 
kit (E30 Mediagnost, Reutlingen, Germany; minimum 
detectable concentration: 0.02 ng/ml).
Western blot Analysis
For dose-response analysis, subconfluent cells were 
incubated in serum-deprived medium for 24 h, stimulated 
with increasing ligand concentrations for 24 h at 37°C and 
solubilized in radioimmune precipitation (RIPA) buffer; 
for time-course experiments, subconfluent cells were 
treated with IGF-I for the indicated time points.
To evaluate IGF-I - dependent activation of DDR1, 
cells were serum-starved for 24 h, and then stimulated 
with IGF-I (50 nM) for 24 h.
Cell lysates were subjected to western blot 
analysis, as previously described [49]. The following 
antibodies were used: anti-DDR1 (C-20, sc-532, Santa 
Cruz Biotechnology), anti-phospho(p)-IR/p-IGF-IR 
(Y1150/Y1151, 3024, Cell Signaling), anti-IGF-IR 
(9750, Cell Signaling), anti-p-AKT (Ser473, 9271, Cell 
Signaling), anti-AKT(9272, Cell Signaling), anti-p-
ERK1/2 (T202/Y204, 4370, Cell Signaling), anti-ERK1/2 
(9102, Cell Signaling), anti-p-p70 (Thr421/Ser424, 
9204, Cell Signaling); anti-p70 (C-18, 230 Santa Cruz 
Biotechnology); anti-α-tubulin (15246, Abcam); anti-actin 
(Sigma). 
Real-time PCR
Total cellular RNA was extracted using TRIzol 
Reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA) 
and miRNAs were isolated with microRNA Purification Kit 
(Norgen Biotek, Thorold Ontario, Canada) according to the 
manufacturer’s protocol. qRT–PCR was used to confirm 
the expression levels of mRNAs and miRNAs. Total RNA 
(1 µg) was reversely transcribed using the ThermoScript 
RT (Invitrogen) and oligo (dT) primers. Total microRNA 
(10 ng) was reversely transcribed using TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems), and 
synthesized cDNA was analyzed in a PCR reaction using 
primers for the gene of interest, as previously described 
[50]. qRT-PCR reactions were performed in a StepOne 
Plus Real-Time PCR System (Applied Biosystems). The 
ΔΔCt method of relative quantification and SYBR Green 
chemistry were used to measure DDR1 mRNA (DDR1 
all FW: 5′-GCGTCTGTCTGCGGGTAGAG-3′, RV: 
5′-ACGGCCTCAGATAAATACATTGTCT-3′), IGF-I 
mRNA (FW: 5′-TCGCATCTCTTCTATCTGGCCCTGT-3′, 
RV: 5′-GCAGTACATCTCCAGCCTCCTCAGA-3′) and 
IGF-II mRNA (FW: 5′-GACCGCGGCTTCTACTTCAG-3′, 
RV: 5′-AAGAACTTGCCCACGGGGTAT-3′). S9 and 
18S were used as endogenous controls for normalization 
(S9, FW: 5′-CTGGGTTTGTCGCAAAACTT-3′; 
RV: 5′-GTGGGTCCTTCTCATCAAGC-3′) (18S, 
FW: 5′-AGGAATTCCCAGTAAGTGCG-3′ RV: 
5′-GCCTCACTAAACCATCCAA-3′). The single-tube 
TaqMan miRNA (Assay ID 000498, Applied Biosystems, 
Life Technologies) was used to detect and quantify mature 
miR-199a-5p according to the manufacturer’s instructions. 
MiR-199a-5p expression was normalized against RNU6B 
expression (Assay ID 001093, Applied Biosystems).
Gene transfection
For microRNA experiments, cells were transfected 
with a mixture containing OptiMEM, RNAimax and either 
100 nM miR-199a-5p or scramble oligonucleotides. For 
gene overexpression experiments, cells were transfected 
with a mixture containing the DNA of interest, OptiMEM 
and Lipofectamine 2000. Twenty-four hours after 
transfection, cells were serum-starved for 24 h and then 
treated with IGF-I (50 nM) for 24 h.
IGF-II transfected cellular clones were generated by 
transfecting MCF-7 and MDA-MB231 cells with pCMV6-
Entry vector and the pCMV6-containing the human IGF-
II gene. After transfection, cells were selected in G-418 
containing medium and subcloned.
Luciferase assay
MCF-7 cells were transiently transfected, as 
described above, with 1 µg of the firefly luciferase 
reporter plasmid containing the 3′UTR of DDR1 cloned in 
pMIR-target vector. Twenty-four hours after transfection, 
cells were incubated with fresh medium and transfected 
with 100 nM of the synthetic miR-199a-5p or scramble 
oligonucleotides using Lipofectamine 2000. Cells were 
stimulated with IGF-I 50 nM for additional 24 h. Firefly 
luciferase activity was detected using the dual-luciferase 
assay Kit (Promega Corporation, Madison, WI, USA) 
48 h after transfection. The luciferase activity was 
normalized to protein absorbance.
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Cell viability
MCF-7 and MDA-MB-231 cell lines were plated 
in 48 wells plates in standard culture medium. After 
24 h, cells were transfected using 100 nM of miR-199a-
5p or scramble oligonucleotides, serum-starved for 24 h, 
and then stimulated with IGF-I 50 nM for additional 24 h. 
Cell viability was then measured by the methyl thiazolyl 
tatrazolium (MTT) test, according to the manufacturer’s 
instructions. Briefly, the cells were incubated with medium 
containing 0.5-mg/mL MTT; after 4 h, the cells were 
dissolved in 100 μL of a solution containing dimethyl 
sulfoxide plus 2.5% complete medium, and formazan 
absorbance was read at 405 nm.
Migration assay 
The ability of cells to invade through fibronectin 
was measured with Boyden’s chamber technique as 
previously described [18, 51]. Cells, serum starved for 
24 h, were placed on polycarbonate filters (8 μm pore size, 
Corning Costar) coated on the upper side with 25 mg/mL 
fibronectin. Filters were placed over bottom chambers 
containing serum-free medium with or without ligand 
(50 nM). After incubation for 3–6 h, depending on the cell 
type, cells on the upper surface of filters were removed 
with a cotton swab, and the filters were stained for 
20 min with crystal violet (0.05% crystal violet in PBS 
plus 20% ethanol). After three washes with water, crystal 
violet was solubilized in 10% acetic acid for 30 min at 
room temperature, and its concentration was evaluated by 
absorbance at 595 nm. 
Computational analysis of microarray gene 
expression
We analyzed the correlation of expression of DDR1 
with DDR2 and with critical receptors and ligands of the 
IGF system (i.e., IGF-IR, INSR, AKT, IGF-I, IGF-II, 
PTEN, IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5) 
across many conditions and many cell and tissues types 
by using the online tool Multi Experiment Matrix (MEM) 
(http://biit.cs.ut.ee/mem/index.cgi). MEM is a repository 
of large collections of microarray datasets that performs 
statistical significance estimation of distances (positive and 
negative expression correlations) by Pearson correlation 
distance; a p-value on the ranks was determined using 
the betaMEM method. We selected Affymetrix GeneChip 
Human Genome U133 plus 2.0 arrays (consisting of 
1794 datasets) for our analysis. We considered betaMEM 
scores ≤ 1 × 10−5 as statistically significant. Moreover, we 
validated the most statistically relevant MEM results on 
The Cancer Genome Atlas (TCGA) breast cancer dataset. 
These latter data were obtained from the TCGA breast 
cancer online portal (https://tcga-data.nci.nih.gov/docs/
publications/brca_2012/). Specifically, we computed 
Pearson coefficient between genes from the microarray 
gene expression data file “BRCA.exp.547.med.txt” that 
consists of 522 primary tumors, 3 metastatic tumors, and 
22 tumor-adjacent normal samples. Data were median 
centered by genes. For this analysis, Pearson coefficients 
with a stringent P-values ≤ 0.00001 were considered 
statistically significant. Data of expression correlation 
between miR-199a-5p and genes from the IGF system 
were retrieved from starBase Pan-Cancer Platform by 
analysis of expression profiles of 14 cancer types from 
TCGA Data Portal [PMID: 24297251].
Densitometric and Statistical analysis
Densitometry results were obtained by using NIH 
ImageJ. Differences between means were evaluated 
by one-way ANOVA followed by post-hoc analysis 
of significance (Bonferroni test) for the comparison 
between more than two groups, whereas the Student’s 
t test for unpaired samples was used for comparisons 
between two groups. The level of significance was set at 
P < 0.05. Statistical analysis was performed with 
GraphPad Prism6 (GraphPad Software, San Diego, CA). 
Data were expressed as mean ± SEM.
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